CYBERDYNE Inc. (CYBQY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CYBERDYNE Inc. (CYBQY) with AI Score 59/100 (Hold). CYBERDYNE Inc. is a Japanese company specializing in the research, development, and production of robotic technologies, including the Hybrid Assistive Limb (HAL). Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026CYBERDYNE Inc. (CYBQY) Healthcare & Pipeline Overview
CYBERDYNE Inc., based in Japan, develops and produces robotic technologies like the Hybrid Assistive Limb (HAL) for medical, welfare, and industrial sectors. With a focus on enhancing physical capabilities, the company operates in a competitive landscape, balancing innovation with financial sustainability, reflected in its negative profit margin.
Investment Thesis
CYBERDYNE Inc. presents a unique investment opportunity in the burgeoning field of medical and industrial robotics. The company's core value driver is its HAL technology, which has applications in healthcare, welfare, and industrial sectors. Growth catalysts include the increasing adoption of robotic rehabilitation therapies and the expansion of HAL into new markets and applications, such as disaster relief and heavy industry. Key metrics to watch include revenue growth from HAL sales and service contracts, as well as progress in clinical trials and regulatory approvals for new medical applications. However, investors should be aware of potential risks, including the company's negative profit margin (-0.1%), which indicates a need for improved cost management and revenue generation. The company's small market capitalization ($0.34B) and OTC listing also introduce liquidity and volatility concerns. The company's P/E ratio is -22098.38. The beta is 0.55.
Based on FMP financials and quantitative analysis
Key Highlights
- CYBERDYNE Inc. operates in the innovative field of robotic exoskeletons with its HAL (Hybrid Assistive Limb) technology.
- The company's HAL technology has applications in medical rehabilitation, industrial support, and disaster relief.
- CYBERDYNE's gross margin stands at 49.9%, indicating a solid foundation for profitability if operational efficiencies improve.
- The company has a market capitalization of $0.34 billion, reflecting its current valuation in the market.
- CYBERDYNE's shares are traded on the OTC market as an ADR (American Depositary Receipt), ticker symbol CYBQY.
Competitors & Peers
Strengths
- Innovative HAL technology with diverse applications.
- Strong brand recognition in the robotics industry.
- Established partnerships with research institutions and healthcare providers.
- First-mover advantage in the robotic exoskeleton market.
Weaknesses
- Negative profit margin indicates financial challenges.
- Small market capitalization and OTC listing raise liquidity concerns.
- Limited geographic presence outside of Japan.
- Reliance on a single core technology (HAL).
Catalysts
- Ongoing: Continued adoption of HAL technology in rehabilitation centers and hospitals.
- Ongoing: Expansion of HAL applications in industrial settings for worker support.
- Upcoming: Potential regulatory approvals for new medical applications of HAL.
- Upcoming: Strategic partnerships with healthcare providers and insurance companies.
- Ongoing: Development of next-generation HAL with AI integration.
Risks
- Ongoing: Negative profit margin indicates financial instability.
- Potential: Competition from established medical device companies and specialized robotics firms.
- Potential: Regulatory hurdles and reimbursement challenges.
- Potential: Technological obsolescence.
- Ongoing: Currency risk associated with the ADR structure.
Growth Opportunities
- Expansion of HAL in Rehabilitation Centers: CYBERDYNE has the opportunity to expand the adoption of its HAL technology in rehabilitation centers globally. The increasing prevalence of stroke and spinal cord injuries drives the demand for advanced rehabilitation solutions. By partnering with leading rehabilitation hospitals and clinics, CYBERDYNE can increase its market penetration. The global rehabilitation equipment market is projected to reach $20 billion by 2028, providing a substantial growth opportunity for CYBERDYNE.
- Industrial Applications of HAL for Enhanced Productivity: CYBERDYNE can capitalize on the growing demand for exoskeletons in industrial settings to enhance worker productivity and reduce workplace injuries. HAL can be deployed in factories, construction sites, and logistics facilities to assist workers with heavy lifting and repetitive tasks. The industrial exoskeleton market is expected to reach $1.8 billion by 2025, offering a significant growth avenue for CYBERDYNE. Success hinges on demonstrating tangible ROI for industrial clients through increased efficiency and reduced injury rates.
- Strategic Partnerships with Healthcare Providers: Forming strategic alliances with healthcare providers and insurance companies can facilitate the adoption of Cybernics Treatment, which utilizes HAL for neurological rehabilitation. These partnerships can streamline the reimbursement process and increase patient access to CYBERDYNE's innovative therapies. The global neurological disease treatment market is projected to reach $15 billion by 2027, creating a substantial market opportunity for CYBERDYNE's Cybernics Treatment.
- Development of Next-Generation HAL with AI Integration: CYBERDYNE can enhance the capabilities of its HAL technology by integrating artificial intelligence (AI) and machine learning algorithms. AI-powered HAL can provide personalized assistance and adapt to individual patient needs, improving rehabilitation outcomes. The integration of AI can also enable predictive maintenance and remote monitoring of HAL devices, reducing downtime and improving customer satisfaction. The AI in healthcare market is expected to reach $34 billion by 2025, providing a technological tailwind for CYBERDYNE's innovation efforts.
- Geographic Expansion into Emerging Markets: CYBERDYNE has the opportunity to expand its presence in emerging markets, such as China, India, and Southeast Asia, where there is a growing demand for advanced medical and industrial technologies. These markets offer significant growth potential due to their large populations, increasing healthcare spending, and growing industrial sectors. However, CYBERDYNE will need to adapt its products and business models to meet the specific needs and regulatory requirements of each market. Success depends on building strong local partnerships and establishing a robust distribution network.
Opportunities
- Expansion into new markets and applications, such as disaster relief and heavy industry.
- Strategic partnerships with healthcare providers and insurance companies.
- Development of next-generation HAL with AI integration.
- Increasing adoption of robotic rehabilitation therapies.
Threats
- Competition from established medical device companies and specialized robotics firms.
- Regulatory hurdles and reimbursement challenges.
- Technological obsolescence.
- Economic downturns affecting healthcare spending.
Competitive Advantages
- Proprietary HAL Technology: CYBERDYNE's HAL technology is protected by patents and trade secrets, creating a barrier to entry for competitors.
- First-Mover Advantage: CYBERDYNE was among the first companies to develop and commercialize robotic exoskeletons, giving it a head start in the market.
- Clinical Evidence: CYBERDYNE has accumulated clinical evidence supporting the efficacy of HAL in improving rehabilitation outcomes, enhancing its credibility with healthcare providers.
- Brand Recognition: CYBERDYNE has established a strong brand reputation in the robotics industry, particularly in Japan.
About CYBQY
CYBERDYNE Inc., founded in 2004 and headquartered in Tsukuba, Japan, is a pioneering robotics company focused on enhancing human capabilities through its innovative Hybrid Assistive Limb (HAL) technology. HAL is designed to assist and rehabilitate individuals with mobility impairments, as well as enhance the physical performance of workers in industrial settings. The company's product portfolio includes HAL for medical use (lower limb and single joint types), non-medical HAL (lower limb, single joint, and lumbar types), HAL peripherals, cleaning robots, and transportation robots for indoor environments. Additionally, CYBERDYNE offers Acoustic X, a high-speed light pulse LED array light source for real-time photoacoustic imaging. CYBERDYNE's services extend to Cybernics Treatment, utilizing HAL to improve function in patients with spinal cord injury, stroke, and neuromuscular diseases. They also provide HAL FIT for brain-nerve-musculoskeletal system enhancement, MTX Neuro HAL Plus for athletes' brain-nerve function enhancement, and Neuro HALFIT for physical function enhancement. Beyond medical and welfare applications, CYBERDYNE is involved in providing rescue support in disaster sites, heavy labor support for factories and plants, and even entertainment applications. The company's global reach is facilitated through its ADR (American Depositary Receipt), CYBQY, allowing US investors to participate in its growth. CYBERDYNE faces competition from other medical device and robotics companies, requiring continuous innovation and strategic partnerships to maintain its market position.
What They Do
- Researches and develops robotic technologies, primarily the Hybrid Assistive Limb (HAL).
- Produces and sells HAL devices for medical, welfare, and industrial applications.
- Leases HAL equipment to various organizations and individuals.
- Maintains and services HAL devices to ensure optimal performance.
- Offers Cybernics Treatment, a rehabilitation therapy using HAL for neurological conditions.
- Provides cleaning and transportation robots for indoor environments.
- Develops and markets Acoustic X, a high-speed light pulse LED array light source for photoacoustic imaging.
- Offers HAL FIT for brain-nerve-musculoskeletal system enhancement.
Business Model
- Direct sales of HAL devices to hospitals, rehabilitation centers, and industrial clients.
- Leasing of HAL equipment to organizations and individuals.
- Service and maintenance contracts for HAL devices.
- Revenue from Cybernics Treatment sessions.
- Sales of HAL peripherals and accessories.
Industry Context
The medical device industry is experiencing rapid growth, driven by technological advancements, an aging population, and increasing demand for innovative healthcare solutions. The robotic rehabilitation market, in particular, is expected to see significant expansion in the coming years. CYBERDYNE operates in this dynamic landscape, competing with established medical device companies and specialized robotics firms. Competitors include BCCOY (Bic Corp), BRSYF (Bristol Myers Squibb), CLLKF (Coloplast A/S), GNFTF (Genfit SA), and JWCTF (JWC Rehabilitation). The company's success will depend on its ability to differentiate its HAL technology, secure regulatory approvals, and establish strategic partnerships.
Key Customers
- Hospitals and rehabilitation centers using HAL for patient rehabilitation.
- Industrial companies deploying HAL to enhance worker productivity and safety.
- Individuals with mobility impairments using HAL for personal assistance.
- Research institutions utilizing HAL for scientific studies.
- Athletes using MTX Neuro HAL Plus to enhance brain-nerve functions.
Financials
Chart & Info
CYBERDYNE Inc. (CYBQY) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Lows On Friday
· Feb 28, 2020
-
Stocks That Hit 52-Week Lows On Thursday
· Feb 27, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CYBQY.
Price Targets
Wall Street price target analysis for CYBQY.
MoonshotScore
What does this score mean?
The MoonshotScore rates CYBQY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Yoshiyuki Sankai
CEO
Yoshiyuki Sankai is the CEO of CYBERDYNE Inc. He is the leading mind behind the HAL technology. His academic background is in engineering, and he has dedicated his career to developing innovative robotic solutions for healthcare and industrial applications. Sankai's expertise lies in the fields of robotics, neuroscience, and cybernetics, which he integrates to create advanced human-machine interfaces. He has received numerous awards and recognition for his contributions to the field of robotics.
Track Record: Under Yoshiyuki Sankai's leadership, CYBERDYNE Inc. has achieved several milestones, including the development and commercialization of the HAL technology. He has overseen the expansion of HAL into new markets and applications, such as disaster relief and heavy industry. Sankai has also forged strategic partnerships with research institutions and healthcare providers to advance the development and adoption of CYBERDYNE's technologies. He has guided the company through regulatory approvals and reimbursement challenges.
CYBERDYNE Inc. ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. CYBERDYNE's ADR, CYBQY, allows U.S. investors to invest in the company without directly dealing with the Japanese stock market. It simplifies trading, as it's denominated in U.S. dollars and trades during U.S. market hours.
- Home Market Ticker: Tokyo Stock Exchange, Japan
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: CYBQ
CYBQY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited financial disclosure and may not meet the listing requirements of major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the lack of regulatory oversight and potential for fraud or manipulation. These companies may be newly formed, distressed, or foreign entities with limited U.S. presence.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: OTC companies often have less stringent reporting requirements, making it difficult to assess their financial health.
- Liquidity Risk: Low trading volumes and wide bid-ask spreads can make it challenging to buy or sell shares.
- Price Volatility: OTC stocks can be more susceptible to price swings due to lower trading volumes and market manipulation.
- Regulatory Risk: OTC companies are subject to less regulatory oversight, increasing the risk of fraud or mismanagement.
- Information Asymmetry: Limited access to information can put investors at a disadvantage compared to insiders.
- Verify the company's registration and legal status.
- Review the company's financial statements, if available.
- Assess the company's management team and track record.
- Research the company's industry and competitive landscape.
- Evaluate the company's business model and growth prospects.
- Check for any regulatory actions or legal disputes.
- Consult with a financial advisor before investing.
- Established Operations: CYBERDYNE Inc. has been in operation since 2004, suggesting a degree of stability.
- HAL Technology: The company's HAL technology has potential applications in healthcare and industrial sectors.
- ADR Listing: The fact that CYBERDYNE has an ADR listing (CYBQY) indicates some level of compliance and transparency.
- CEO Leadership: Yoshiyuki Sankai is the CEO of CYBERDYNE Inc.
Common Questions About CYBQY
What does CYBERDYNE Inc. do?
CYBERDYNE Inc. is a Japanese robotics company specializing in the development, production, and distribution of the Hybrid Assistive Limb (HAL). HAL is a wearable robotic device designed to assist and enhance the physical capabilities of its users. The company operates in the medical, welfare, and industrial sectors, providing solutions for rehabilitation, mobility assistance, and workplace productivity. CYBERDYNE's business model revolves around the sale, lease, and maintenance of HAL devices, as well as the provision of Cybernics Treatment, a rehabilitation therapy utilizing HAL for neurological conditions.
What do analysts say about CYBQY stock?
As of March 16, 2026, formal analyst ratings for CYBQY are limited due to its OTC market listing and smaller market capitalization. Investors should conduct their own due diligence and consider the company's financial performance, growth prospects, and risk factors before making any investment decisions. Key valuation metrics include the company's price-to-earnings ratio (-22098.38), gross margin (49.9%), and market capitalization ($0.34 billion). Growth considerations include the potential for HAL to expand into new markets and applications, as well as the company's ability to improve its profitability.
What are the main risks for CYBQY?
CYBERDYNE Inc. faces several risks, including its negative profit margin, which indicates financial instability. The company also faces competition from established medical device companies and specialized robotics firms. Regulatory hurdles and reimbursement challenges could hinder the adoption of HAL in healthcare settings. Technological obsolescence is another risk, as advancements in robotics and artificial intelligence could render HAL less competitive. Finally, currency risk associated with the ADR structure could impact the value of CYBQY for U.S. investors.
What are the key factors to evaluate for CYBQY?
CYBERDYNE Inc. (CYBQY) currently holds an AI score of 59/100, indicating moderate score. Key strength: Innovative HAL technology with diverse applications.. Primary risk to monitor: Ongoing: Negative profit margin indicates financial instability.. This is not financial advice.
How frequently does CYBQY data refresh on this page?
CYBQY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CYBQY's recent stock price performance?
Recent price movement in CYBERDYNE Inc. (CYBQY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative HAL technology with diverse applications.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CYBQY overvalued or undervalued right now?
Determining whether CYBERDYNE Inc. (CYBQY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CYBQY?
Before investing in CYBERDYNE Inc. (CYBQY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage for CYBQY due to its OTC listing.
- Financial data based on available information as of March 16, 2026.